Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacokinetics of tacrolimus following an overdose in a patient with extreme obesity and genotype CYP3A53/3: a case report.

The Journal of toxicological sciences - 1 Jan 2022

Hirai Toshinori, Morikawa Yoshihiko, Sasaki Noriko, Kato Hideo, Nakato Daisuke, Hirayama Masahiro, Kaneko Tadashi, Imai Hiroshi, Iwamoto Takuya

Abstract excerpt

This case involved a 27-year-old man with extreme obesity (body mass index 45.6 kg/m2) who had a history of fulminant hepatitis and living-donor liver transplantation at 11 years of age. He had been receiving oral sustained-release tacrolimus (TAC) 1.5 mg daily, and the trough concentration in the blood was below 2.0 ng/mL. He has an intrinsic cytochrome P450 3A5 (CYP3A5)*3/*3 (G/G) genotype and graft liver with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP3A
Share to Genotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunosuppressive Agents

Share to Kidney Transplantation

Share to Liver Transplantation

Share to Living Donors

Share to Obesity

Share to Tacrolimus

Source

Identifiers

PMID: 35110472
DOI: 10.2131/jts.47.71

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacokinetics of tacrolimus following an overdose in a patient with extreme obesity and genotype CYP3A5*3/*3: a case report.PMID 35110472Read ↗

Unusual high dose of tacrolimus in liver transplant patient, a case report.Semantic proximity Read ↗

Physiologically based pharmacokinetic modeling of tacrolimus for food-drug and CYP3A drug-drug-gene interaction predictions.Semantic proximity Read ↗

Tacrolimus Elimination in Four Patients With a CYP 3A5*3/*3 CYP 3A4*22/*22 Genotype CombinationSemantic proximity Read ↗

Reduced variability of tacrolimus trough level in once-daily tacrolimus-based Taiwanese kidney transplant recipients with high-expressive genotype of cytochrome P450 3A5.Semantic proximity Read ↗

Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics.Semantic proximity Read ↗

Physiologically based pharmacokinetic model combined with reverse dose method to study the nephrotoxic tolerance dose of tacrolimus.Semantic proximity Read ↗

Tacrolimus nephrotoxicity: beware of the association of diarrhea, drug interaction and pharmacogenetics.Semantic proximity Read ↗

Investigation of pharmacologic interactions between omeprazole and tacrolimus in a membranous nephropathy patient with CYP3A5 nonexpresser: a case report.Semantic proximity Read ↗

How to handle missed or delayed doses of tacrolimus in renal transplant recipients? A pharmacokinetic investigation.Semantic proximity Read ↗

Influence of ABCB1 C3435T polymorphism on the pharmacokinetics of lansoprazole and gastroesophageal symptoms in Japanese renal transplant recipients classified as CYP2C19 extensive metabolizers and treated with tacrolimus.Semantic proximity Read ↗

Busulfan pharmacokinetics in adults – a real-world evaluation of intra-individual variabil-ity and the impact of obesity and deferasiroxSemantic proximity Read ↗

Effect of hepar-protecting Wuzhi capsule on pharmacokinetics and dose-effect character of tacrolimus in healthy volunteers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.